Abstract
Background: The clinicopathological manifestations and treatment outcomes of bone metastasis of gastric cancer are largely unknown. We delineated a prognostic model to identify different risk groups on the basis of clinical parameters. Methods: Patients who had bone metastasis at the time of diagnosis of gastric cancer (synchronous metastasis) or who developed bone metastasis during follow-up (metachronous metastasis) were retrospectively reviewed from January 1998 to May 2008. Results: Bone metastasis was identified in 203 (2.4%) of 8,633 patients: 126 patients (62%) with synchronous metastasis and 77 patients with metachronous metastasis. The median time to event was 16 months (range 4-87). As for treatment, 120 patients (59%) received systemic chemotherapy. The median survival time was 103 days (95% CI 80-126). Poor performance status [Eastern Cooperative Oncology Group 3-4; relative risk (RR) = 1.91, p = 0.011], multiple bone metastasis (RR = 2.593, p = 0.002), and abnormal carcinoembryonic antigen (RR = 1.779, p = 0.004) implied independent factors for survival. For patients who had zero to two of these factors identified, chemotherapy had a beneficial effect (175 vs. 43 days; p < 0.0001). Conclusion: We recommend that the therapeutic approach with bone metastasis be customized to facilitate the risk stratification, so as to consequently provide the most appropriate therapy for each patient.
| Original language | English |
|---|---|
| Pages (from-to) | 142-150 |
| Number of pages | 9 |
| Journal | Oncology |
| Volume | 80 |
| Issue number | 1-2 |
| DOIs | |
| Publication status | Published - 2011 Jun 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
}
A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. / Park, Hyung Soon; Rha, Sun Young; Kim, Hyo Song; Hyung, Woo Jin; Park, Ji Soo; Chung, Hyun Cheol; Noh, Sung Hoon; Jeung, Hei Cheul.
In: Oncology, Vol. 80, No. 1-2, 01.06.2011, p. 142-150.Research output: Contribution to journal › Review article
TY - JOUR
T1 - A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis
AU - Park, Hyung Soon
AU - Rha, Sun Young
AU - Kim, Hyo Song
AU - Hyung, Woo Jin
AU - Park, Ji Soo
AU - Chung, Hyun Cheol
AU - Noh, Sung Hoon
AU - Jeung, Hei Cheul
PY - 2011/6/1
Y1 - 2011/6/1
N2 - Background: The clinicopathological manifestations and treatment outcomes of bone metastasis of gastric cancer are largely unknown. We delineated a prognostic model to identify different risk groups on the basis of clinical parameters. Methods: Patients who had bone metastasis at the time of diagnosis of gastric cancer (synchronous metastasis) or who developed bone metastasis during follow-up (metachronous metastasis) were retrospectively reviewed from January 1998 to May 2008. Results: Bone metastasis was identified in 203 (2.4%) of 8,633 patients: 126 patients (62%) with synchronous metastasis and 77 patients with metachronous metastasis. The median time to event was 16 months (range 4-87). As for treatment, 120 patients (59%) received systemic chemotherapy. The median survival time was 103 days (95% CI 80-126). Poor performance status [Eastern Cooperative Oncology Group 3-4; relative risk (RR) = 1.91, p = 0.011], multiple bone metastasis (RR = 2.593, p = 0.002), and abnormal carcinoembryonic antigen (RR = 1.779, p = 0.004) implied independent factors for survival. For patients who had zero to two of these factors identified, chemotherapy had a beneficial effect (175 vs. 43 days; p < 0.0001). Conclusion: We recommend that the therapeutic approach with bone metastasis be customized to facilitate the risk stratification, so as to consequently provide the most appropriate therapy for each patient.
AB - Background: The clinicopathological manifestations and treatment outcomes of bone metastasis of gastric cancer are largely unknown. We delineated a prognostic model to identify different risk groups on the basis of clinical parameters. Methods: Patients who had bone metastasis at the time of diagnosis of gastric cancer (synchronous metastasis) or who developed bone metastasis during follow-up (metachronous metastasis) were retrospectively reviewed from January 1998 to May 2008. Results: Bone metastasis was identified in 203 (2.4%) of 8,633 patients: 126 patients (62%) with synchronous metastasis and 77 patients with metachronous metastasis. The median time to event was 16 months (range 4-87). As for treatment, 120 patients (59%) received systemic chemotherapy. The median survival time was 103 days (95% CI 80-126). Poor performance status [Eastern Cooperative Oncology Group 3-4; relative risk (RR) = 1.91, p = 0.011], multiple bone metastasis (RR = 2.593, p = 0.002), and abnormal carcinoembryonic antigen (RR = 1.779, p = 0.004) implied independent factors for survival. For patients who had zero to two of these factors identified, chemotherapy had a beneficial effect (175 vs. 43 days; p < 0.0001). Conclusion: We recommend that the therapeutic approach with bone metastasis be customized to facilitate the risk stratification, so as to consequently provide the most appropriate therapy for each patient.
UR - http://www.scopus.com/inward/record.url?scp=79958770676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958770676&partnerID=8YFLogxK
U2 - 10.1159/000328507
DO - 10.1159/000328507
M3 - Review article
C2 - 21677462
AN - SCOPUS:79958770676
VL - 80
SP - 142
EP - 150
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 1-2
ER -